P129, a pyrazole ring-containing isolongifolanone-derivate: synthesis and investigation of anti-glioma action mechanism
Open Access
- 6 January 2024
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-22
Abstract
Background: Cyclin-dependent kinase-2 (CDK-2) is an important regulatory factor in the G1/S phase transition. CDK-2 targeting has been shown to suppress the viability of multiple cancers. However, the exploration and application of a CDK-2 inhibitor in the treatment of glioblastoma are sparse. Methods: We synthesized P129 based on isolongifolanone, a natural product with anti-tumor activity. Network pharmacology analysis was conducted to predict the structural stability, affinity, and pharmacological and toxicological properties of P129. Binding analysis and CETSA verified the ability of P129 to target CDK-2. The effect of P129 on the biological behavior of glioma cells was analyzed by the cell counting kit-8, colony formation, flow cytometry, and other experiments. Western blotting was used to detect the expression changes of proteins involved in the cell cycle, cell apoptosis, and epithelial–mesenchymal transition. Results: Bioinformatics analysis and CETSA showed that P129 exhibited good intestinal absorption and blood–brain barrier penetrability together with high stability and affinity with CDK-2, with no developmental toxicity. The viability, proliferation, and migration of human glioma cells were significantly inhibited by P129 in a dose- and time-dependent manner. Flow cytometry and western blotting analyses showed G0/G1 arrest and lower CDK-2 expression in cells treated with P129 than in the controls. The apoptotic ratio of glioma cells increased significantly with increasing concentrations of P129 combined with karyopyknosis and karyorrhexis. Apoptosis occurred via the mitochondrial pathway. Conclusion: The pyrazole ring-containing isolongifolanone derivate P129 exhibited promising anti-glioma activity by targeting CDK-2 and promoting apoptosis, indicating its potential importance as a new chemotherapeutic option for glioma.Keywords
Funding Information
- Natural Science Foundation of Jiangsu Province (BK20220611)
- Jilin Province Science and Technology Development Planning Project (20200801023GH)
- Health and Wellness Technology Enhancement Project of Jilin Province (2022LC105)
- The S&T Development Planning Program of Jilin Province (YDZJ202201ZYTS073, 20200404101YY)
- National Nature and Science Foundation of China (81672505)
- Jilin Province Medical and Health Talent Project (JLSWSRCZX 2021-052)
This publication has 53 references indexed in Scilit:
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patientsProceedings of the National Academy of Sciences, 2011
- Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculataClinical Cancer Research, 2010
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase CatastropheClinical Cancer Research, 2010
- Inhibition of Cyclin-dependent Kinase-2 Induces Apoptosis in Human Diffuse Large B-cell LymphomasCell Cycle, 2007
- Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathwayProceedings of the National Academy of Sciences, 2007
- CDK2-Dependent Phosphorylation of FOXO1 as an Apoptotic Response to DNA DamageScience, 2006
- Phosphorylation of Progesterone Receptor Serine 400 Mediates Ligand-Independent Transcriptional Activity in Response to Activation of Cyclin-Dependent Protein Kinase 2Molecular and Cellular Biology, 2004
- Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor FlavopiridolClinical Cancer Research, 2004
- Cyclin D1 Overexpression Induces Progestin Resistance in T-47D Breast Cancer Cells Despite p27Kip1 Association with Cyclin E-Cdk2Journal of Biological Chemistry, 2001